Application of Salivary Biomarkers in the Diagnosis of Fibromyalgia
Metadatos
Afficher la notice complèteAuteur
Illescas Montes, Rebeca; Costela Ruiz, Víctor Javier; Melguizo Rodríguez, Lucía; Luna Bertos, María Elvira De; Ruiz Rodríguez, Concepción; Ramos Torrecillas, JavierEditorial
Mdpi
Materia
Fibromyalgia Saliva Biomarkers Diagnosis
Date
2021-01-03Referencia bibliográfica
Illescas-Montes, R.; Costela-Ruiz, V.J.; Melguizo- ARodríguez, L.; De Luna-Bertos, E.; Ruiz, C.; Ramos-Torrecillas, J. Application of Salivary Biomarkers in the Diagnosis of Fibromyalgia. Diagnostics 2021, 11, 63. [https://doi.org/10.3390/diagnostics11010063]
Patrocinador
Junta de Andalucía BIO277; Department of Nursing (University of Granada)Résumé
Fibromyalgia (FM) is a highly prevalent syndrome that impairs the quality of life of the
patients; however, its diagnosis is complex and mainly centered on pain symptoms. The study of
salivary biomarkers has proven highly useful for the diagnosis and prognosis of numerous diseases.
The objective of this review was to gather published data on the utilization of salivary biomarkers to
facilitate and complement the diagnosis of FM. Salivary biomarkers used in FM diagnosis include
cortisol; calgranulin; and the enzymes -amylase, transaldolase, and phosphoglycerate mutase.
Increased serum levels of C-reactive protein, cytokines interleukin 1- , interleukin 6, interleukin
8, interleukin 10, interleukin 17, tumor necrosis factor , and various chemokines may serve as
salivary biomarkers, given observations of their increased serum levels in patients with FM. Further
research is warranted to study in depth the role and performance of biomarkers currently used in
FM diagnosis/prognosis and to identify novel salivary biomarkers for this disease.